BioNTech Non Currrent Assets Other vs Non Current Liabilities Total Analysis

BNTX Stock

USD 90.13 0.75 0.83%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Non Currrent Assets Other and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Non Currrent Assets Other vs Non Current Liabilities Total

Non Currrent Assets Other vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Non Currrent Assets Other account and Non Current Liabilities Total. At this time, the significance of the direction appears to have strong relationship.

The correlation between BioNTech's Non Currrent Assets Other and Non Current Liabilities Total is 0.69. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Non Currrent Assets Other and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of BioNTech SE are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Non Currrent Assets Other i.e., BioNTech's Non Currrent Assets Other and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Non Current Liabilities Total

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.82	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.75	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.96	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.82	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.4	0.57	0.78	0.53	0.82	0.43	0.58	0.87	0.66	0.89	0.4	0.74	0.77	0.56
Other Current Liab	0.82	0.82		0.99	0.79	0.72	0.34	-0.64	0.76	0.63	0.64	0.48	0.28	0.58	0.96	0.38	0.59	0.3	0.46	0.98	0.65	0.98	0.28	0.68	0.85	0.04
Total Current Liabilities	0.85	0.88	0.99		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.36	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.7	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.79	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.78	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.97	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.72	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.82	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.98	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.34	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.67	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.64	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.74	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.98	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.76	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.8	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.97	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.63	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.89	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.95	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.64	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.76	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.99	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.48	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.97	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.93	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97		0.87	0.15	0.99	0.41	1.0	0.69	0.41	0.82	0.41	1.0	0.87	0.71	0.15
Cash And Short Term Investments	0.94	0.57	0.58	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.87		0.39	0.89	0.55	0.85	0.58	0.67	0.99	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.96	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.15	0.39		0.25	0.52	0.17	0.37	0.91	0.47	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.38	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.86	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.59	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.41	0.55	0.52	0.49		0.42	0.35	0.66	0.6	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.3	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.81	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.58	0.46	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.69	0.58	0.37	0.73	0.35	0.72		0.6	0.58	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.98	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.41	0.67	0.91	0.51	0.66	0.43	0.6		0.73	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.96	0.66	0.65	0.7	0.97	0.98	0.67	-0.98	0.97	0.95	0.99	0.93	0.82	0.99	0.47	0.86	0.6	0.81	0.58	0.73		0.71	0.82	0.97	0.94	0.23
Total Liab	0.86	0.89	0.98	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.41	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.71		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.82	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.68	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.87	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.97	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.77	0.85	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.71	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.94	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.04	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.15	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.23	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	68.9M	240.2M	301.5M	212.2M	219.1M	161.3M
Other Current Liab	16.4M	103.1M	3.0B	2.6B	1.3B	979.8M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	83.4M	87.6M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	61.0M	64.9M	271.9M	280.9M	294.9M
Other Stockholder Equity	(5.5M)	1.5B	(3.8M)	(5.3M)	1.2B	1.3B
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	(984.6M)	(935.4M)
Short Term Debt	7.6M	9.1M	129.9M	36M	28.1M	32.9M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	804.1M	844.3M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

BioNTech Investors Sentiment

The influence of BioNTech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioNTech. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioNTech's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioNTech.

BioNTech Implied Volatility

30.34

BioNTech's implied volatility exposes the market's sentiment of BioNTech SE stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if BioNTech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that BioNTech stock will not fluctuate a lot when BioNTech's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioNTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioNTech's short interest history, or implied volatility extrapolated from BioNTech options trading.

Pair Trading with BioNTech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.

Moving against BioNTech Stock

0.65	VRCA	Verrica Pharmaceuticals Financial Report 14th of May 2024	Pair Corr
0.46	HOOK	Hookipa Pharma	Pair Corr
0.45	VIRI	Virios Therapeutics Llc	Pair Corr

The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.

The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

4.11

Revenue Per Share

15.873

Quarterly Revenue Growth

(0.65)

Return On Assets

0.0262

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Non Currrent Assets Other vs Non Current Liabilities Total Analysis

Non Currrent Assets Other vs Non Current Liabilities Total

Non Currrent Assets Other vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Non Current Liabilities Total

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

BioNTech Investors Sentiment

BioNTech Implied Volatility

Pair Trading with BioNTech

Moving against BioNTech Stock

Complementary Tools for BioNTech Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Other Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net